Amlodipine competes fiercely with a 20 billion fast-moving retail terminal of blood pressure reduction

In recent years, the market of high blood pressure drugs has been growing under the huge demand of high blood pressure people in China However, in 2015-2016, the overall growth rate of hypertension drug market declined due to the impact of bidding price reduction, medical insurance fee control and economic growth slowdown With the change of situation, the growth rate of hypertension drug market will leave the downturn At the annual meeting of aha2017, the American Heart Association and the American Heart Association jointly released the new version of the American hypertension guidelines, which is an update 14 years later A new definition, a new threshold, a new target value and a new measurement method are proposed Hypertension was defined as blood pressure over 130 / 80mmHg For the elderly aged > 65, the new version of the guide is a big flip of the previous version The study found that intensive antihypertensive treatment significantly reduced the risk of cardiovascular disease, but did not increase the risk of falls and postural hypotension, which led to the shuffle of the global hypertension treatment market Some domestic experts believe that there are differences in cardiovascular diseases between Eurasians For example, coronary heart disease has a greater threat to Caucasians, while Asian people have a greater risk of stroke Whether this standard can be adopted in China still needs to be evaluated by experts However, in 2015, the Lancet medical journal has mentioned that lowering blood pressure to 130 / 75mmhg can significantly reduce the risk of cardiovascular and cerebrovascular diseases The cause of hypertension is complex, blood pressure is easy to fluctuate, and the choice of drug type and dosage affects the effect of hypertension It has been proved in practice that the risk of cardiovascular and cerebrovascular diseases is in a decreasing trend after the treatment of many elderly hypertension in China reaches the standard   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> hypertension challenges human beings According to a study in the lancet, the number of people suffering from hypertension in the world has increased to 1.13 billion, and 17 million people die of cardiovascular diseases every year During the 45 years from 1958 to 2002, four investigations on hypertension were completed in China At present, the National Cardiovascular Center is organizing the fifth national survey of hypertension population In June 2015, the Ministry of health released the prevalence rate of hypertension in the population aged 18 years or over in China was 25.2%, with 278 million patients Chronic diseases have become a major problem affecting the health of residents The prevalence of chronic diseases was higher in the elderly The prevalence of hypertension in the elderly aged 65 and over was 52.4% With the comprehensive coverage of the national medical insurance system and the health concern of the middle-aged and elderly, the awareness rate, treatment rate and control rate of the hypertension population have reached 46%, 41% and 14%, respectively, which has made great progress compared with the beginning of this century, but still can not be ignored In recent years, the market of high blood pressure drugs has been growing under the demand of large population of high blood pressure in China However, in 2015-2016, the overall growth rate of hypertension drug market declined due to the impact of bidding price reduction, medical insurance fee control and economic growth slowdown However, with the change of the situation, the growth rate of hypertension drug market will leave the downturn     none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box side: border box! Im portant; word wrap: break word! Im portant; "> the retail market of anti hypertension in domestic pharmacies can reach nearly 20 billion yuan In 2016, the retail market of domestic pharmacies was 337.7 billion yuan, an increase of 9.18% over the previous year The chemical drug market accounts for 49.52% of the total retail terminal drug market In 2016, the retail terminal market of antihypertensive drugs was 15.9 billion yuan, an increase of 3.92% over the previous year Under the background of great health and the guidance of national policies, it is expected that the retail market of anti hypertension in domestic pharmacies will reach nearly 20 billion in 2017 In 2016, there were 15 generic drugs in the top 100 categories of antihypertensive retail terminal drugs market The market share is 14.317 billion yuan Among them, the top 10 varieties accounted for 70.22% of the retail antihypertensive market of domestic pharmacies, and other varieties accounted for 29.78% According to the data, the retail market of antihypertensive drug stores in China shows the situation of nifedipine, amlodipine and L-amlodipine in three aspects, accounting for 40% of the retail market of antihypertensive drug stores   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> amlodipine is the third generation of calcium antagonists, which is a drug for the treatment of chronic stable angina and hypertension of coronary heart disease, can reduce the risk of hospitalization and coronary artery reconstruction The original drug was developed by Pfizer So far, CFDA has issued 98 approvals for amlodipine More than 70 enterprises have competed in this market The competition is very fierce, and there are not a few domestic famous brands According to the data of minenet, in 2016, the sales volume of amlodipine in domestic retail pharmacies reached 2.435 billion yuan, an increase of 7.22% over the previous year, accounting for nearly one third of the total market of amlodipine terminals in China The top 5 brands of amlodipine are Luo Huoxi of Pfizer, Ya Shida of China Resources SECCO pharmaceutical, Randy of Shanghai haini company of Yangtze River Pharmaceutical, an neizhen of Suzhou Dongrui pharmaceutical, and Xin Luoping of Kunming sanuo pharmaceutical In the domestic public hospitals and urban community terminals, the original research drugs dominate the whole world, accounting for more than 90% of the market, while in the retail drugstores, the original research drugs and domestic drugs are equally divided under the price factor; in the case of the increase of medical insurance drugstores and the temporary inability to connect medical insurance remote clinics, it is estimated that the amlodipine market in domestic retail drugstores will reach 2.6 billion in 2017 To 3 billion yuan market scale   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> the second generation of nifedipine is highly competitive The second generation of nifedipine refers to nifedipine controlled-release tablets and nifedipine sustained-release tablets Nifedipine is the first generation of calcium antagonists After the innovation of drug release technology, nifedipine is the second generation of calcium antagonists and plays an important role in clinical Nifedipine, in addition to lowering blood pressure, has effects on variant angina, unstable angina and chronic stable angina, so it is the competitive advantage of nifedipine in the market According to data from minenet, the total sales volume of nifedipine in domestic retail pharmacies in 2016 was 2.585 billion yuan, an increase of 8.61% over the previous year It is worth mentioning that nifedipine controlled-release tablets amounted to 1.448 billion yuan, accounting for 56.02% of the total, an increase of 14.38% over the previous year Nifedipine sustained-release tablets were 1.137 billion yuan, with an increase rate of 2.06% In addition, the price of nifedipine is low, the dosage of nifedipine is decreasing gradually, and the proportion of nifedipine is less Nifedipine controlled-release tablet is a kind of tablet with constant release rate and stable efficacy, which is superior to the sustained-release tablet The main brand of nifedipine controlled-release tablet sold in China is baxintong of Bayer, Germany, followed by Xinran of Shanghai Hyundai In China, nifedipine sustained-release preparations include tablets and capsules, which are registered with 27 companies The competition is fierce Nifuda of Qingdao Huanghai Pharmaceutical Co., Ltd., Huyou of Jiangsu Pharmaceutical Co., Ltd., jiubaoping of Beijing Honglin Pharmaceutical Co., Ltd and Shengtongping of Guangdong Global Pharmaceutical Co., Ltd are among the best   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> L-amlodipine is the third generation of calcium antagonists At the end of the 20th century, L-amlodipine was successfully developed and listed in China L-amlodipine is the L-isomer of amlodipine Compared with amlodipine, L-amlodipine has the characteristics of good efficacy, small adverse reactions and small dosage L-amlodipine will be easy to cause side effects such as edema and no hypotensive effect of the "right-handed body" to split, and retain the hypotensive effect of the left-handed body At present, CFDA has issued 31 registration approvals, and 12 enterprises produce L-amlodipine preparations According to the data of minenet, in 2016, the sales of L-amlodipine in domestic retail pharmacies reached 1.569 billion yuan, an increase of 1.88% over the previous year, and it is predicted that the market of retail pharmacies will reach 1.837 billion yuan in 2017 In clinic, L-amlodipine is especially suitable for the elderly patients with coronary heart disease Now, L-amlodipine has been used as the first-line drug in the treatment of hypertension, stable angina and variant angina L-amlodipine is one of the main types of calcium channel blockers Many new processes and technologies of L-amlodipine have been developed in China It is reported that several domestic companies have disclosed the invention patents of the drug Since the R & D of L-amlodipine was successfully launched in 1999, after several enterprises continued to tackle key problems, its crystal content and purity have been improved, impurities have been reduced, and the stability of drug quality has been guaranteed Therefore, L-amlodipine has become a better drug than amlodipine, which is a strong growing variety in the market of differential antihypertensive drugs in China.